

Cover Story
Conversation with The Cancer LetterFree
Stanford Cancer Institute earned the NCI Comprehensive Cancer Center designation, becoming the eighth institution in California to earn this highest level of recognition.
In Brief
Drugs & Targets
Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- CBER Director Vinay Prasad dared to “say no to drugs”
- Reforms pending at USPSTF, plus, FDA rejects promising melanoma drug for the second time














